http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 08:41:30 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Scotiabank analyst Orest Wowkodaw raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK42.00 (from SEK36.00) while maintaining a Sector Outperform rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Mon, 15 Jun 2026 08:41:30 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Scotiabank analyst Orest Wowkodaw raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK42.00 (from SEK36.00) while maintaining a Sector Outperform rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Mon, 15 Jun 2026 08:41:30 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Scotiabank analyst Orest Wowkodaw raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK42.00 (from SEK36.00) while maintaining a Sector Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Mon, 15 Jun 2026 08:41:30 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Scotiabank analyst Orest Wowkodaw raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK42.00 (from SEK36.00) while maintaining a Sector Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK42+at+Scotiabank/26644820.html Mon, 15 Jun 2026 08:41:30 -0400 LMC http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/Press+Releases/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.ftwort" idsrc="xmltag.org" >FORT WORTH, Texas</location></span>, <span class="legendSpanClass"><chron>May 20, 2026</chron></span> /PRNewswire/ -- Legacy <span value="ACORN:1360344567" idsrc="xmltag.org" >Medical Consultants</span>, a leading provider of allografts for the treatment of hard-to-heal chronic wounds, today announced the initiation of the REBOUND clinical trial: a prospective, post-market randomized controlled study evaluating Orion™, a dual-layer amniotic membrane allograft for the management of diabetic foot ulcers (DFUs) in adults ages 50 to 85 years old.</p> <p>The study, formally titled "A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management," is registered as NCT06420245 http://www.streetinsider.com/PRNewswire/Legacy+Medical+Consultants+Announces+Initiation+of+REBOUND+Clinical+Trial+Evaluating+Orion%E2%84%A2+Amniotic+Membrane+Allograft+for+Diabetic+Foot+Ulcers/26525737.html Wed, 20 May 2026 09:00:00 -0400 A.13603445 A.33151435 LMC O.02147044 O.20446507 http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Morgan Stanley analyst Ioannis Masvoulas raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK260.00 (from SEK237.90) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Tue, 12 May 2026 05:10:12 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Morgan Stanley analyst Ioannis Masvoulas raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK260.00 (from SEK237.90) while maintaining a Equalweight rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Tue, 12 May 2026 05:10:12 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Morgan Stanley analyst Ioannis Masvoulas raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK260.00 (from SEK237.90) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Tue, 12 May 2026 05:10:12 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Morgan Stanley analyst Ioannis Masvoulas raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to SEK260.00 (from SEK237.90) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+SEK260+at+Morgan+Stanley/26471814.html Tue, 12 May 2026 05:10:12 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Canaccord analyst Dalton Baretto raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$46.00 (from Cdn$41.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Tue, 21 Apr 2026 12:26:27 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Canaccord analyst Dalton Baretto raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$46.00 (from Cdn$41.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Tue, 21 Apr 2026 12:26:27 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Canaccord analyst Dalton Baretto raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$46.00 (from Cdn$41.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Tue, 21 Apr 2026 12:26:27 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Canaccord analyst Dalton Baretto raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$46.00 (from Cdn$41.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2446+at+Canaccord/26342612.html Tue, 21 Apr 2026 12:26:27 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html CIBC analyst Anita Soni raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$41.00 (from Cdn$39.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html Tue, 21 Apr 2026 12:09:36 -0400 LMC http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html CIBC analyst Anita Soni raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$41.00 (from Cdn$39.00) while maintaining a Neutral rating. http://www.streetinsider.com/Intl+Ratings/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html Tue, 21 Apr 2026 12:09:36 -0400 LMC http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html CIBC analyst Anita Soni raised the price target on Lundin Mining Corp. (LUN:CN) (NYSE: LMC) to Cdn$41.00 (from Cdn$39.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Lundin+Mining+Corp.+%28LUN%3ACN%29+%28LMC%29+PT+Raised+to+Cdn%2441+at+CIBC/26342518.html Tue, 21 Apr 2026 12:09:36 -0400 LMC